Streetbeat News

EDSA

Edesa Biotech, Inc.

https://www.edesabiotech.com

Industry

Biotechnology

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Open

2.15

Mkt cap

7.2M

Volume

25K

High

2.32

P/E Ratio

-0.11

52-wk high

6.46

Low

2.12

Div yield

N/A

52-wk low

2.09

ReShape Lifesciences Inc. (RSLS) shares soared by approximately 45% in pre-market trading due to FDA PMA supplement approval for its Lap-Band 2.0 FLEX. Other stocks also experienced significant movement in pre-market trading, with various gainers such as RiskOn International, Inc. (ROI) and C4 Therapeutics, Inc. (CCCC), and losers including Jin Medical International Ltd. (ZJYL) and Altisource Asset Management Corporation (AAMC).

Portfolio Pulse from Avi Kapoor

December 13, 2023 | 12:55 pm

HC Wainwright & Co. analyst Vernon Bernardino has maintained a Buy rating on Edesa Biotech (NASDAQ:EDSA) but has reduced the price target from $70 to $21. This adjustment reflects a significant change in the expected future performance of the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 11:35 am

Urban Outfitters, Inc. (NASDAQ:URBN) shares dropped by approximately 10% despite reporting Q3 earnings of 88 cents per share, above the consensus estimate of 82 cents, and record sales of $1.28 billion, surpassing expectations of $1.26 billion. Other stocks experienced movements in Wednesday's mid-day session, with notable gainers including AgileThought, Inc. (AGIL), PaxMedica, Inc. (PXMD), and SciSparc Ltd. (SPRC), among others. Losers included Alterity Therapeutics Limited (ATHE), MIRA Pharmaceuticals, Inc. (MIRA), and Tharimmune, Inc. (THAR), with companies like Guess?, Inc. (GES), Nordstrom, Inc. (JWN), and Deere & Company (DE) also reporting declines after their financial results.

Portfolio Pulse from Lisa Levin

November 22, 2023 | 7:03 pm

HC Wainwright & Co. analyst Vernon Bernardino reaffirmed a Buy rating on Edesa Biotech (NASDAQ:EDSA) and maintained a $10 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 11:34 am

Edesa Biotech announced that its 1.0% formulation for dermatitis has reached the primary endpoint with statistical significance in its final Phase 2b study. The full analysis also revealed additional efficacy signals.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:09 pm

Health Canada has approved Edesa Biotech's proposal to harmonize clinical trial designs in the U.S. and Canada for an ongoing Phase 3 study of EB05 (paridiprubart).

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:15 pm

The article lists the stocks that gained and lost the most during Friday's mid-day trading session. Among the gainers were Sigma Additive Solutions, Bio-Path Holdings, and Shift Technologies, while the losers included Bellerophon Therapeutics, Outset Medical, and MSP Recovery. The article also mentions several companies that reported better-than-expected earnings, such as Comtech Telecommunications and JPMorgan Chase, and others that lowered their guidance or reported worse-than-expected results, such as Belden and SMART Global Holdings.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 5:14 pm

Benzinga's Stock Whisper Index highlights five stocks that warrant attention for the week of Oct. 13, 2023. These include Edesa Biotech Inc (EDSA), which announced a reverse stock split and secured a financial commitment from Canada's government for a Phase 3 clinical study; Palantir Technologies (PLTR), which secured a $250 million contract from the U.S. Department of Defense; Akero Therapeutics (AKRO), which saw a sharp drop in shares after disappointing Phase 2b study results; Tupperware Brands Corp (TUP), which saw increased volatility and trading after amendments to an existing credit agreement; and Plug Power Inc (PLUG), which saw increased investor attention after updating its long-term revenue guidance.

Portfolio Pulse from Chris Katje

October 13, 2023 | 2:26 pm

Shares of several companies including Oblong, Bio-Path Holdings, Blue Star Foods, Versus Systems, RedHill Biopharma, Datasea, Shift Technologies, Getaround, Scienjoy Holding, and Comtech Telecommunications surged in pre-market trading. Comtech's shares rose after posting better-than-expected Q4 results. On the other hand, shares of Cassava Sciences, SMART Global Holdings, BeyondSpring, Edesa Biotech, ReShape Lifesciences, Momentus, LogicMark, Society Pass, Tian Ruixiang Holdings, and ParaZero Technologies fell in pre-market trading.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 11:35 am

Edesa Biotech Inc (NASDAQ:EDSA) has secured a commitment of up to C$23 million from the Government of Canada for a Phase 3 clinical study of the company's first-in-class therapeutic candidate, EB05. The drug, which reduced mortality by 84% among critically ill patients with ARDS in a Phase 2 study, is designed to modulate the body's immune response to infectious diseases. The funding will be used for study expenses and scale-up of commercial drug product if successful. EDSA shares are up 81.50% at $4.90.

Portfolio Pulse from Vandana Singh

October 12, 2023 | 6:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.